Cambridge Cognition wins second partnership for Alzheimer's platform

Cambridge Cognition has won a second commercial partnership with a leading pharmaceutical company for its NeuroVocalix voice biomarker technology platform.

The AIM-traded company said it has partnered with an unnamed top 10 global pharmaceutical company that has licenced the technology for its next virtual trial, with the software set to be deployed directly onto participants' own smartphones in order to allow them to engage in the testing protocol from the comfort of their own homes.

The platform, which is particularly aimed at helping patients with Alzheimer's, was launched last year and is intended to assist with the logistics and costs of clinical trials where verbal neuropsychological tests are employed.

The first NeuroVocalix contract was signed in September, leading to the platform's involvement in a four-week study with a global pharmaceutical company.

Matthew Stork, chief executive of Cambridge Cognition said: "Providing automated verbal testing and at the same time identifying voice biomarkers during clinical trials could help accelerate and improve the quality of clinical trials, benefiting patients across the world and providing a major opportunity for Cambridge Cognition."

Cambridge Cognition shares were up 7.98% at 61.01p at 0850 BST.